Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| NYSE | USD | Real-time | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Frankfurt | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Hamburg | EUR | Delayed | ||
| Xetra | EUR | Delayed | ||
| Santiago | USD | Delayed | ||
| Buenos Aires | ARS | Delayed | ||
| BM&FBovespa | BRL | Delayed | ||
| Vienna | EUR | Delayed | ||
| KASE | USD | Delayed | ||
| Colombia | COP | Delayed | ||
| Lima | USD | Delayed |
Wednesday's top analyst upgrades and downgrades included Alcoa, Cloudflare, Foot Locker, Fortinet, Lockheed Martin, On Semiconductor, Ovintiv, Pfizer, Take-Two Interactive...
Newark, New Castle, USA, Feb. 08, 2023 (GLOBE NEWSWIRE) -- The global "Activated Phosphoinositide 3-Kinase Delta Syndrome (APDS) Market Size" is expected to rise with an...
Experts Want Labels For Pfizer, Moderna COVID-19 Vaccines Updated To Acknowledge Limitations Authored by Zachary Stieber via The Epoch Times (emphasis ours), A coalition of experts...
'The Scandal Would Be Enormous': Pfizer Director Worried About Vax-Induced Menstrual Irregularities Project Veritas on Thursday released a new segment of undercover footage of...
Pfizer CEO Made 'Misleading' Statements On Vaccinating Children Against COVID-19: UK Watchdog Authored by Lily Zhou via The Epoch Times (emphasis ours), Pfizer CEO Albert Bourla...
Pfizer Inc. is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products around the world. The Company operations through two segments: Biopharma and PC1. Biopharma is a science-based medicines business that includes six therapeutic areas, such as Vaccines, Hospital, Oncology, Internal Medicine, Rare Disease, and Inflammation & Immunology. PC1 is its global contract development and manufacturing organization and supplier of specialty active pharmaceutical ingredients. Its Vaccines include Comirnaty/BNT162b2, the Prevnar family, Nimenrix and others. Its Oncology products include Ibrance, Xtandi, Inlyta, Sutent, Retacrit, Lorbrena and Braftovi. Its Internal Medicine products include Eliquis and the Premarin family. Its Inflammation & Immunology products include Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis and Cibinqo. It also offers Rimegepant and Zavegepant.
| Average | 52.79 (+20.03% Upside) |
| High | 75.00 |
| Low | 40.00 |
| Price | 43.98 |
| No. of Analysts | 19 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Buy | Sell | Neutral |
| Technical Indicators | Buy | Strong Buy | Strong Buy | Strong Sell | Strong Sell |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Sell | Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 48.12 | 48.19 | 47.65 | +0.020 | +0.04% | 2.44M | Sydney | |||
| 215.36 | 217.35 | 215.01 | -1.02 | -0.47% | 24.39K | Sydney | |||
| 4.04 | 4.13 | 4.02 | 0.00 | 0.00% | 0.00 | Sydney | |||
| 306.73 | 309.42 | 305.30 | +0.52 | +0.17% | 141.88K | Sydney | |||
| 110.22 | 110.60 | 109.59 | -0.100 | -0.09% | 448.49K | Sydney | |||
| 0.36 | 0.38 | 0.37 | -0.01 | -2.67% | 8.56K | Sydney | |||
| 0.028 | 0.028 | 0.028 | +0.001 | +3.70% | 161.23K | Sydney | |||
| 4.535 | 4.585 | 4.535 | -0.045 | -0.98% | 641.54K | Sydney | |||
| 79.57 | 81.39 | 78.84 | -2.01 | -2.46% | 213.78K | Sydney | |||
| 7.29 | 7.35 | 7.23 | -0.040 | -0.55% | 445.43K | Sydney | |||
Healthscopederived | 0.022 | 0.02 | 2.46 | 0.00 | 0.00% | 0.00 | Sydney | ||
| 0.006 | 0.007 | 0.006 | 0.00 | 0.00% | 0.00 | Sydney | |||
| 0.019 | 0.019 | 0.019 | 0.00 | 0.00% | 0.00 | Sydney | |||
| 0.009 | 0.009 | 0.009 | 0.00 | 0.00% | 0.00 | Sydney | |||
| 0.002 | 0.002 | 0.002 | 0.00 | 0.00% | 187.50K | Sydney |